Kamada is a plasma-derived biopharmaceutical company focused on orphan indications, with an existing marketed product portfolio and a late-stage product pipeline. Co. uses its platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived immune globulins. Co.'s activity is divided into two operating segments: Proprietary Products, which includes the development, manufacturing, sales and distribution of plasma-derived protein therapeutics; and Distribution, which distributes imported drug products in Israel that are manufactured by third parties. The KMDA stock yearly return is shown above.
The yearly return on the KMDA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the KMDA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|